Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B(TM) in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)

Stock Information for Longeveron Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Longeveron Inc.

Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Longeveron to Present at the Planet MicroCap Showcase
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
Longeveron Announces Closing of $5.2 Million Public Offering
Longeveron Announces Pricing of $5.25 Million Public Offering
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
Longeveron Announces 1-for-10 Reverse Stock Split

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.